Pazopanib for the first-line treatment of advanced renal cell carcinoma

Technology appraisal guidance
Reference number: TA215
Published: 23 February 2011
Last updated: 01 August 2013

TA215 Pazopanib for the first-line treatment of renal cell carcinoma -Appendix A: provisional matrix of stakeholders

TA215 Pazopanib for the first-line treatment of renal cell carcinoma -Appendix A: provisional matrix of stakeholders

TA215 Pazopanib for the first-line treatment of renal cell carcinoma -Appendix A: provisional matrix of stakeholders
09 September 2013
(104.91 Kb 30 sec)

Adobe Acrobat reader required.

Adobe Acrobat reader required.

This page was last updated: 09 September 2013